1. Home
  2. ARBE vs MNOV Comparison

ARBE vs MNOV Comparison

Compare ARBE & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

HOLD

Current Price

$0.89

Market Cap

79.1M

Sector

Technology

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.37

Market Cap

67.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARBE
MNOV
Founded
2015
2000
Country
Israel
United States
Employees
144
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
67.9M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ARBE
MNOV
Price
$0.89
$1.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$2.38
$7.50
AVG Volume (30 Days)
1.6M
70.7K
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
$363.94
N/A
Revenue Next Year
$286.43
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.55
$1.17
52 Week High
$2.88
$1.96

Technical Indicators

Market Signals
Indicator
ARBE
MNOV
Relative Strength Index (RSI) 54.95 52.87
Support Level $0.77 $1.29
Resistance Level $0.90 $1.51
Average True Range (ATR) 0.07 0.05
MACD 0.01 0.00
Stochastic Oscillator 88.81 40.35

Price Performance

Historical Comparison
ARBE
MNOV

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: